US20020183553A1 - Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof - Google Patents

Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof Download PDF

Info

Publication number
US20020183553A1
US20020183553A1 US10/000,428 US42801A US2002183553A1 US 20020183553 A1 US20020183553 A1 US 20020183553A1 US 42801 A US42801 A US 42801A US 2002183553 A1 US2002183553 A1 US 2002183553A1
Authority
US
United States
Prior art keywords
venlafaxine
purity
base
venlafaxine hydrochloride
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/000,428
Other languages
English (en)
Inventor
Ben-Zion Dolitzky
Judith Aronhime
Shlomit Wizel
Gennady Nisnevich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals USA Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/000,428 priority Critical patent/US20020183553A1/en
Priority to KR10-2004-7008012A priority patent/KR20040068163A/ko
Priority to MXPA04005193A priority patent/MXPA04005193A/es
Priority to CNA2007101970607A priority patent/CN101219962A/zh
Priority to PCT/US2002/037268 priority patent/WO2003048082A2/en
Priority to CA002468728A priority patent/CA2468728A1/en
Priority to AU2002365874A priority patent/AU2002365874A1/en
Priority to HU0700037A priority patent/HUP0700037A2/hu
Priority to JP2003549277A priority patent/JP2005511668A/ja
Priority to ZA200404080A priority patent/ZA200404080B/en
Priority to CNA028276485A priority patent/CN1617848A/zh
Priority to IL16217102A priority patent/IL162171A0/xx
Priority to EP02791279A priority patent/EP1474379A4/de
Priority to PL02374273A priority patent/PL374273A1/xx
Publication of US20020183553A1 publication Critical patent/US20020183553A1/en
Assigned to TEVA PHARMACEUTICAL INDUSTRIES LTD. reassignment TEVA PHARMACEUTICAL INDUSTRIES LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NISNEVICH, GENNADY A., ARONHIME, JUDITH, DOLITZKY, BEN-ZION, WIZEL, SHLOMIT
Assigned to TEVA PHARMACEUTICAL USA, INC. reassignment TEVA PHARMACEUTICAL USA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Priority to IS7289A priority patent/IS7289A/is
Priority to US10/863,958 priority patent/US20040220278A1/en
Priority to HR20040565A priority patent/HRP20040565A2/xx
Priority to NO20042732A priority patent/NO20042732L/no
Priority to US10/961,337 priority patent/US6924393B2/en
Priority to US12/075,875 priority patent/US20080167498A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C07C217/70—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • Venlafaxine ( ⁇ )-1-[2-(Dimethylamino)-1-(4-ethyoxyphenyl) ethyl] cyclo-hexanol, having the following formula I, is the first of a class of anti-depressants. Venlafaxine acts by inhibiting re-uptake of norepinephrine and serotonin, and is an alternative to the tricyclic anti-depressants and selective re-uptake inhibitors.
  • U.S. Pat. No. 4,535,186 (the '186 patent) describes the process for the preparation of venlafaxine hydrochloride via the intermediate venlafaxine base.
  • the entirety of the '186 patent is incorporated herein by reference.
  • the '186 patent does not describe whether the venlafaxine so obtained is solid.
  • venlafaxine is in the form of white crystals, with a purity of 99.3% or greater as confirmed by high pressure liquid chromatography (HPLC).
  • crystalline venlafaxine can be prepared from venlafaxine hydrochloride by methylation of N,N-didesmethyl venlafaxine by means of a novel process.
  • the present invention relates to an essentially pure venlafaxine.
  • the present invention relates to an essentially pure venlafaxine hydrochloride.
  • the present invention provides a process of preparing venlafaxine base from venlafaxine hydrochloride.
  • the present invention provides a process of preparing venlafaxine base by alkylation of N,N-didesmethyl venlafaxine.
  • the present invention provides crystalline venlafaxine base, wherein the venlafaxine base is white crystal with about 97% purity.
  • the present invention provides crystalline venlafaxine base, wherein the venlafaxine base is white crystal with about 98% purity.
  • the present invention provides crystalline venlafaxine base, wherein the venlafaxine base is white crystal with about 99% purity.
  • the present invention provides crystalline venlafaxine base, wherein the venlafaxine base is white crystal with about 99.3% purity.
  • the present invention provides crystalline venlafaxine base, wherein the venlafaxine base is white crystal with about 99.5% purity.
  • the present invention relates to a process for the preparation of an essentially pure venlafaxine hydrochloride via the solid venlafaxine.
  • the present invention relates to two novel polymorphs of venlafaxine hydrochloride denominated as Form I and Form II as well as solvate forms of venlafaxine hydrochloride denominated as Form III and Form IV.
  • the present invention provides a process for preparation of the anhydrous Form I by dissolving the compound in water and precipitating it by adding DMF (dimethyl formamide) or MEK (methylethylketone).
  • the present invention provides a process for preparation of the solvate Form III by dissolving the compound in a protic solvent such as water, ethanol or methanol and precipitating it by adding an aprotic solvent like acetone, ethylacetate, isopropylether or tert-butylmethylether (MTBE).
  • a protic solvent such as water, ethanol or methanol
  • an aprotic solvent like acetone, ethylacetate, isopropylether or tert-butylmethylether (MTBE).
  • the present invention provides a process for preparation of the solvate Form III by dissolving the compound in chloroform and precipitating it by adding hexane or toluene.
  • the present invention provides processes for preparation of the solvate Form III by crystallizing the compound in absolute ethanol or isopropyl alcohol.
  • the present invention provides processes for preparation of the solvate Form III by triturating the compound in aprotic solvents such as ethyl acetate, isopropyl ether or hexane.
  • aprotic solvents such as ethyl acetate, isopropyl ether or hexane.
  • the present invention provides processes for preparation of the solvate Form IV by crystallizing the compound in DMF (dimethyl formamide) and DMSO (dimethyl sulfoxide), or by dissolving the compound in water and precipitating it by adding DMSO.
  • DMF dimethyl formamide
  • DMSO dimethyl sulfoxide
  • the present invention provides a process for preparing venlafaxine hydrochloride from venlafaxine base.
  • the present invention provides a process of preparing venlafaxine hydrochloride comprises the step of forming a mixture of venlafaxine, preferably venlafaxine base, in acetone and exposing the mixture in gaseous hydrochloric acid (HCl).
  • a process of preparing venlafaxine hydrochloride comprises the step of forming a mixture of venlafaxine, preferably venlafaxine base, in acetone and exposing the mixture in gaseous hydrochloric acid (HCl).
  • HCl hydrochloric acid
  • Preferable pH is about 6 to about 7.5. Most preferable pH is about 7.
  • the present invention provides a process of preparing venlafaxine hydrochloride comprises exposing a homogeneous solution of venlafaxine/acetone in gaseous hydrochloric acid (HCl).
  • HCl gaseous hydrochloric acid
  • the present invention provides a process of preparing venlafaxine hydrochloride comprises exposing a homogeneous solution of venlafaxine/isopropanol in gaseous hydrochloric acid (HCl).
  • HCl gaseous hydrochloric acid
  • the present invention provides preparing a homogenous solution of venlafaxine in a solution where venlafaxine is substantially insoluble or limited solubility, preferably acetone or isopropanol.
  • the present invention provides processes for preparing venlafaxine Form I and Form II.
  • the present invention provides a process for preparing venlafaxine hydrochloride comprising the steps of: 1) preparing a mixture (or a homogeneous solution) of venlafaxine, preferably venlafaxine base, with acetone; and 2) exposing the mixture in gaseous hydrochloric acid (HCl).
  • the present invention provides a process for preparing venlafaxine hydrochloride comprising the steps of: 1) preparing a mixture of venlafaxine in isopropanol; and 2) exposing the mixture in gaseous hydrochloric acid at a range of pH.
  • the pH ranges from about pH 5 to about pH 8.
  • Preferably the pH ranges from about pH 6 to about pH 7.5.
  • Most preferably the pH is at about pH 7.
  • the present invention provides venlafaxine hydrochloride, where the venlafaxine hydrochloride is white crystal with about 99.92% purity.
  • the present invention provides a process for preparing venlafaxine hydrochloride Form I comprises triturating venlafaxine hydrochloride with acetone followed by drying upon stirring under reduced pressure and crystallizing venlafaxine hydrochloride.
  • the present invention provides venlafaxine hydrochloride Form I as prepared by a process comprises triturating venlafaxine hydrochloride with acetone followed by drying upon stirring under reduced pressure and crystallizing venlafaxine hydrochloride.
  • the present invention provides a process for preparing venlafaxine hydrochloride Form I comprises triturating venlafaxine hydrochloride with isopropanol followed by drying upon stirring under reduced pressure and crystallizing venlafaxine hydrochloride.
  • the present invention provides venlafaxine hydrochloride Form I as prepared by a process comprises triturating venlafaxine hydrochloride with isopropanol followed by drying upon stirring under reduced pressure and crystallizing venlafaxine hydrochloride.
  • the present invention provides venlafaxine hydrochloride Form I, where the venlafaxine hydrochloride Form I is white crystal with about 99.95% purity.
  • the present invention provides a process for preparing venlafaxine hydrochloride Form II comprises triturating venlafaxine hydrochloride with acetone or isopropanol followed by drying in a tray under reduced pressure and crystallizing venlafaxine hydrochloride.
  • the present invention provides venlafaxine hydrochloride Form II as prepared by a process of triturating venlafaxine hydrochloride with acetone or isopropanol followed by drying in a tray under reduced pressure and crystallizing venlafaxine hydrochloride.
  • the present invention provides venlafaxine hydrochloride Form II, where the venlafaxine hydrochloride Form II is white crystal with about 99.95% purity.
  • FIG. 1 represents the Differential Scanning Calorimetry (DSC) curve of Venlafaxine Hydrochloride Form I.
  • FIG. 2 represents the powder x-ray diffractogram (PXRD) of Venlafaxine Hydrochloride Form I.
  • FIG. 3 represents the DSC curve of Venlafaxine Hydrochloride Form II.
  • FIG. 4 represents the PXRD of Venlafaxine Hydrochloride Form II.
  • FIG. 5 represents the DSC curve of Venlafaxine Hydrochloride Form III.
  • FIG. 6 represents the PXRD of Venlafaxine Hydrochloride Form III.
  • FIG. 7 represents the DSC curve of Venlafaxine Hydrochloride Form IV.
  • FIG. 8 represents the PXRD of Venlafaxine Hydrochloride Form IV.
  • FIG. 9 represents the PXRD of crystalline Venlafaxine Base.
  • FIG. 10 represents the schematic process for preparing Venlafaxine Hydrohloride from Venlafaxine Base in the presence of Hydrochloride Acid (HCl) gas and acetone.
  • Hydrochloride Acid HCl
  • DMF dimethyl formamide
  • MEK methylethylketone
  • MTBE tert-butylmethylether
  • DMSO dimethyl sulfoxide
  • DSC Differential Scanning Calorimetry
  • PXRD powder x-ray diffractogram
  • IPA isopropyl alcohol
  • HCl hydrochloric acid
  • the present invention relates to essentially pure venlafaxine which, surprisingly, can be obtained in the form of free base.
  • the venlafaxine base exists in a solid crystalline form.
  • An essentially pure venlafaxine is prepared by adding sodium hydroxide to an aqueous solution of venlafaxine hydrochloride. Another preferable alkali solution is potassium hydroxide. The resulting mixture was extracted by an organic solvent. The extraction can be performed using ethyl acetate, heptane, hexane and a mixture thereof. The extraction solvent is preferably ethyl acetate. The combined organic layers are dried, preferably over anhydrous sodium sulfate, and evaporated. The residue is then crystallized from hexane or heptane.
  • the crystals so obtained are filtered off, washed with cold hexane or heptane and dried to give solid venlafaxine, with purity of 99.3% or greater.
  • the purity of solid venlafaxine is generally greater than about 97%, preferably greater than about 98% and most preferably greater than about 99%.
  • the solid venlafaxine is further reacted with hydrochloric acid and crystallized to yield an essentially pure venlafaxine hydrochloride.
  • N,N-didesmethyl venlafaxine (20 mmole) was added to water (480 mL), formic acid (88.5%, 5.2 grams, ⁇ 100 mmole), formaldehyde (35.8%, 5 grams, 62 mmole) at room temperature. The obtained mixture was stirred under reflux conditions during 21 hours and cooled to room temperature. The pH was adjusted to about 11 with 32% aqueous solution of NaOH. Potassium hydroxide can be equivalently used to adjust to pH to about 11. The pH-adjusted mixture was extracted with toluene (50 mL ⁇ 5).
  • the present invention provides a process for the purification of venlafaxine hydrochloride comprising basifying the venlafaxine hydochloride.
  • the present invention provides a process for the purification of venlafaxine hydochloride further comprising crystallizing the venlafaxine.
  • the present invention provides a process for the purification of venlafaxine hydochloride further comprising reacting the venlafaxine so prepared with hydrochloric acid and crystallization to regenerate venlafaxine hydrochloride in a higher state of purity.
  • the purity of venlafaxine hydrochloride is generally greater than about 97%, preferably greater than 98% and most preferably greater than about 99%.
  • Venlafaxine hydrochloride is obtained according to the process as described in U.S. Pat. No. 4,535,186, which is incorporated herewith in reference.
  • the present invention relates to a novel polymorphic form of venlafaxine hydrochloride, denominated Form I.
  • This crystal form is characterized by unique strong X-ray peaks at about 10.2, 15.5, 20.3, 21.7 ⁇ 0.2 degrees two-theta, and medium peaks at 6.7, 13.5, 18.2, 19.8, 22.6, 25.6, 28.1, 35.1 ⁇ 0.2 degrees two-theta.
  • the DSC thermogram of Form I includes an endotherm at about 210-213 degrees due to melting.
  • the present invention relates to a novel polymorphic form of venlafaxine hydrochloride, denominated Form II.
  • This crystal form is characterized by unique strong X-ray peaks at about 12.8, 20.5, 21.3 ⁇ 0.2 degrees two-theta, and medium peaks at 6.8, 8.5, 10.3,13.6, 15.6, 16.5, 19.8, 19.9, 21.9, 25.2, 28.7, 31.2, 31.7, 35.3 ⁇ 0.2 degrees two-theta.
  • the DSC thermogram of Form II includes an endotherm at about 210-213 degrees due to melting; a phase transformation is often observed with a resulting peak at about 219-222 degrees. This transformation may occur at different extents and probably is concomitant to a sublimation phenomenon.
  • the present invention relates to a novel solvate crystal form of venlafaxine hydrochloride, denominated Form III.
  • This crystal form is characterized by unique strong X-ray peaks at about 7.4, 14.9, 26.5 ⁇ 0.2 degrees two-theta, and medium peaks at about 12.9, 16.4, 17.5, 18.6, 18.9, 20.5, 21.4, 38.2 ⁇ 0.2 degrees two-theta.
  • the DSC thermogram of Form III includes a broad endotherm due to desolvatation, a small endotherm in the range of approximately 180-200 degrees and an endotherm at about 212 degrees, due to melting.
  • This solvated form may include water, or methanol, ethanol or hexane.
  • the loss on drying values range between about 5.6%-6.0% for the compounds that contain methanol or ethanol, about 4.6% for the compound that contains isopropyl alcohol, and about 5.5% for the compound that contains hexane.
  • the present invention relates to a novel solvate crystal form of venlafaxine hydrochloride, denominated Form IV.
  • This crystal form is characterized by unique strong X-ray peaks at about 10.3, 20.3 ⁇ 0.2 degrees two-theta, and medium peaks at about 6.8, 13.5, 15.6, 21.8, 27.2, 35.2 ⁇ 0.2 degrees two-theta.
  • the DSC thermogram of Form IV includes a broad endotherm due to desolvatation, and an endotherm at about 212 degrees due to melting.
  • This solvated crystal form may include DMSO or DMF.
  • the loss on drying value, as determined in the TGA, is about 41% in the compound crystallized in DMSO, and about 33% in the compound crystallized in DMF. These values—about 41% and 33%—correspond to the stoichiometric values of 3 molecules of DMSO and 2 molecules of DMF per molecule of Venlafaxine hydrochloride. From this we deduce that solvated Form IV may be a trisolvate of DMSO and disolvate of DMF.
  • the present invention discloses processes for preparation of the different polymorphic forms of venlafaxine hydrochloride.
  • Form III can form solvates with different solvents, such as ethanol, methanol, or isopropanol.
  • venlafaxine hydrochloride is dissolved in protic solvents (i.e., solvents that have a hydroxide [—OH] group) like water, ethanol or methanol, and an aprotic solvent (i.e., a solvent that lacks a hydroxide [—OH] group) such as acetone, ethyl acetate, isopropyl ether or tert-butylmetylether (MTBE) is added to produce solvate Form III.
  • protic solvents i.e., solvents that have a hydroxide [—OH] group
  • an aprotic solvent i.e., a solvent that lacks a hydroxide [—OH] group
  • MTBE tert-butylmetylether
  • Heating rate 10° C./min
  • Heating rate 10° C./min
  • Venlafaxine hydrochloride was dissolved in water under reflux. Acetone was added. The suspension formed is refluxed additional ten minutes and exposed at room temperature overnight. Afterward the suspension is filtered, washed with about 2 mL of the same mixture of solvents. The solid obtained is crystallized in Form III. Further drying in a rotavapor under a reduced pressure ( ⁇ 10 mbar) over about 45 minutes at about 60 degrees produced Form I.
  • Venlafaxine hydrochloride was dissolved in methanol under reflux. Ethyl acetate, or isopropyl ether, or MTBE was added. The suspension formed is refluxed additional ten minutes and exposed at room temperature overnight. Afterward the suspension is filtered, washed with 2 ml of the same mixture of solvents. The solid obtained is crystallized in Form III. Further drying in a rotavapor under a reduced pressure ( ⁇ 10 mbar) over about 45 minutes at about 60 degrees produced Form I.
  • Venlafaxine hydrochloride was dissolved in the solvent under reflux. The antisolvent was added. The suspension formed is refluxed additional ten minutes and exposed at room temperature overnight. Afterward the suspension is filtered, washed with 2 ml of the same mixture of solvents. The solid obtained is crystallized in Form III. Further drying in a rotavapor under a reduced pressure ( ⁇ 10 mbar) over about 45 minutes at about 60 degrees produced mixtures of Form II, or Form I., or a mixture of the two forms.
  • Venlafaxine hydrochloride (2 grams) was dissolved in ethanol (8 mL) or in isopropyl alcohol (10 mL) under reflux and the solution was left overnight at room temperature. The crystallized material was filtered and washed with 2 ml of the same solvent. The solid obtained is crystallized in Form III. Further drying in a rotavapor under a reduced pressure ( ⁇ 10 mbar) over about 45 minutes at about 60 degrees produced Form II, or Form I, or a mixture of the two forms.
  • Venlafaxine hydrochloride (2 grams) was dissolved in DMF or DMSO (8 ml) under reflux and the solution was left overnight at room temperature. The crystallized material was filtered and washed with 2 ml of the same solvent. The solid obtained is crystallized in Form III. Further drying in a rotavapor under a reduced pressure ( ⁇ 10 mbar) over about 45 minutes at about 60 degrees produced Form II, or Form I, or a mixture of the two forms.
  • Venlafaxine hyrdrochloride was dissolved in water under reflux. The antisolvent was added. The suspension formed is refluxed additional ten minutes and exposed at room temperature overnight. Afterward the suspension is filtered, washed with 2 mL of the same mixture of solvents. The solid obtained is crystallized in Form I. Further drying in a rotavapor under a reduced pressure ( ⁇ 10 mbar) over about 45 minutes at about 60 degrees produced Form I.
  • Venlafaxine hydrochloride was dissolved in methanol at about 0-5° C. The antisolvent was added. The suspension formed is stirred for 30 minutes. Afterward the suspension is filtered, washed with 2 ml of the same mixture of solvents. The solid obtained is crystallized in Form II. Further drying in a rotavapor under a reduced pressure ( ⁇ 10 mbar) over about 45 minutes at about 60 degrees produced Form II.
  • the present invention provides a process for preparing venlafaxine hydrochloride.
  • the process comprises exposing venlafaxine base to gaseous hydrochloric acid (HCl).
  • FIG. 10 The schematic process for preparing venlafaxine hydrochloride from venlafaxine base is illustrated in FIG. 10.
  • the theoretical yield of the product is about 31.34 grams (i.e., 100 mmol).
  • a 1-L double-jacketed reactor equipped with a mechanical stirrer, a thermometer, a pH-electrode and PTFE deep tube was charged with venlafaxine base (about 27.7 grams) and acetone (about 526 grams). The mixture was stirred for about 20 min at room temperature until a homogeneous solution was achieved.
  • the crude venlafaxine hydrochloride (about 15.0 grams) was triturated with acetone (about 60.0 grams) for about 1 hour at about 60° C. and for about 1 hour at about 0° C., filtered off, washed on filter with cold acetone (about 120 grams) and dried in a tray under reduced pressure at about 50° C. (water bath) to a constant weight to give about 14.8 grams (about 93.2%) of venlafaxine hydrochloride as white crystals with purity of about 99.95% by HPLC.
  • Venlafaxine base (1 Kg) was dissolved in isopropanol (6 L). Hydrochloric acid (gas) was bubbled until a pH ranging from about pH 5 to about pH 8 was achieved, at ⁇ 20° C. Preferably, the pH ranges from pH about 6 to pH about 7.5. Most preferably, the pH is at about pH 7. The reaction mixture was heated to clear solution and cooled gradually to 10° C. The precipitate was filtered and washed with isopropanol and dried in vacuum.
  • Hydrochloric acid gas

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
US10/000,428 2000-10-19 2001-11-30 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof Abandoned US20020183553A1 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
US10/000,428 US20020183553A1 (en) 2000-10-19 2001-11-30 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
CNA2007101970607A CN101219962A (zh) 2001-11-30 2002-11-20 结晶文拉法辛碱、新的盐酸文拉法辛多晶型物及它们的制备方法
CNA028276485A CN1617848A (zh) 2001-11-30 2002-11-20 结晶文拉法辛碱、新的盐酸文拉法辛多晶型物及它们的制备方法
IL16217102A IL162171A0 (en) 2001-11-30 2002-11-20 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
PCT/US2002/037268 WO2003048082A2 (en) 2001-11-30 2002-11-20 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
CA002468728A CA2468728A1 (en) 2001-11-30 2002-11-20 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
AU2002365874A AU2002365874A1 (en) 2001-11-30 2002-11-20 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
HU0700037A HUP0700037A2 (en) 2001-11-30 2002-11-20 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
JP2003549277A JP2005511668A (ja) 2001-11-30 2002-11-20 結晶性ベンラファキシン塩基及びベンラファキシン塩酸塩の新規多形、並びにそれらの製法
ZA200404080A ZA200404080B (en) 2001-11-30 2002-11-20 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
PL02374273A PL374273A1 (en) 2001-11-30 2002-11-20 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
KR10-2004-7008012A KR20040068163A (ko) 2001-11-30 2002-11-20 결정질 벤라팍신 염기 및 벤라팍신 히드로클로라이드의신규한 다형태, 이의 제조 방법
EP02791279A EP1474379A4 (de) 2001-11-30 2002-11-20 Kristalline venlafaxinbase und neue polymorphe von venlafaxinhydrochlorid, verfahren zu deren herstellung
MXPA04005193A MXPA04005193A (es) 2001-11-30 2002-11-20 Base de venlafaxina cristalina y polimorfos nuevos de hidrocloruro de venlafaxina, procesos para la preparacion de los mismos.
IS7289A IS7289A (is) 2001-11-30 2004-05-27 Kristallaður venlafaxínbasi og nýir fjölgervingarvenlafaxínhýdróklóríðs, aðferðir til að framleiðaþá
US10/863,958 US20040220278A1 (en) 2000-10-19 2004-06-08 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
HR20040565A HRP20040565A2 (en) 2001-11-30 2004-06-17 Crystalline venlafaxine base and novel polymorphsof venlafaxine hidrochloride, processes for preparing thereof
NO20042732A NO20042732L (no) 2001-11-30 2004-06-29 Krystallinsk venlafaksin-base og nye polymorfe former av venlafaksin-hydroklorid samt fremgangsmater for fremstilling derav
US10/961,337 US6924393B2 (en) 2000-10-19 2004-10-07 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US12/075,875 US20080167498A1 (en) 2000-10-19 2008-03-13 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24157700P 2000-10-19 2000-10-19
US25886100P 2000-12-29 2000-12-29
US27872101P 2001-03-26 2001-03-26
US29246901P 2001-05-21 2001-05-21
US10/000,428 US20020183553A1 (en) 2000-10-19 2001-11-30 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/045,510 Continuation-In-Part US20020143211A1 (en) 2000-10-19 2001-10-19 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochlorid, processes for preparing thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/863,958 Division US20040220278A1 (en) 2000-10-19 2004-06-08 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US10/961,337 Division US6924393B2 (en) 2000-10-19 2004-10-07 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof

Publications (1)

Publication Number Publication Date
US20020183553A1 true US20020183553A1 (en) 2002-12-05

Family

ID=21691493

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/000,428 Abandoned US20020183553A1 (en) 2000-10-19 2001-11-30 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US10/863,958 Abandoned US20040220278A1 (en) 2000-10-19 2004-06-08 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US10/961,337 Expired - Fee Related US6924393B2 (en) 2000-10-19 2004-10-07 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US12/075,875 Abandoned US20080167498A1 (en) 2000-10-19 2008-03-13 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
US10/863,958 Abandoned US20040220278A1 (en) 2000-10-19 2004-06-08 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US10/961,337 Expired - Fee Related US6924393B2 (en) 2000-10-19 2004-10-07 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US12/075,875 Abandoned US20080167498A1 (en) 2000-10-19 2008-03-13 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof

Country Status (16)

Country Link
US (4) US20020183553A1 (de)
EP (1) EP1474379A4 (de)
JP (1) JP2005511668A (de)
KR (1) KR20040068163A (de)
CN (2) CN1617848A (de)
AU (1) AU2002365874A1 (de)
CA (1) CA2468728A1 (de)
HR (1) HRP20040565A2 (de)
HU (1) HUP0700037A2 (de)
IL (1) IL162171A0 (de)
IS (1) IS7289A (de)
MX (1) MXPA04005193A (de)
NO (1) NO20042732L (de)
PL (1) PL374273A1 (de)
WO (1) WO2003048082A2 (de)
ZA (1) ZA200404080B (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105359A1 (en) * 2000-10-31 2003-06-05 Van Der Schaaf Paul Adriaan Crystalline forms of venlafaxine hydrochloride
US20030109585A1 (en) * 2001-12-05 2003-06-12 Wyeth Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
US20030114536A1 (en) * 2001-12-05 2003-06-19 Wyeth Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
WO2003082806A1 (en) * 2002-03-28 2003-10-09 Synthon B.V. Venlafaxine base

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20031298A3 (cs) * 2000-10-19 2003-10-15 Teva Pharmaceutical Industries Ltd. Způsob přípravy krystalické báze venlafaxinu a nových polymorfů hydrochloridu venlafaxinu
DE10359154A1 (de) * 2003-12-16 2005-07-28 Krka Tovarna Zdravil, D.D. Verfahren zur Herstellung von Venlafaxin und Venlafaxinhydrochlorid der Form I
US7456317B2 (en) * 2005-12-01 2008-11-25 Auspex Pharmaceuticals Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
EP1824815A2 (de) * 2005-10-19 2007-08-29 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung von hochreinem 1-[2-dimethylamino-(4-methoxyphenyl)ethyl]cyclohexanol-hydrochlorid
US20080234257A1 (en) * 2007-03-15 2008-09-25 Auspex Pharmaceuticals, Inc. Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
CN101279926A (zh) * 2008-05-22 2008-10-08 杭州盛美医药科技开发有限公司 盐酸文拉法辛晶型FormⅠ的制备方法
IN2015DN01662A (de) 2012-09-18 2015-07-03 Auspex Pharmaceuticals Inc
TWI788702B (zh) 2013-11-15 2023-01-01 美商阿克比治療有限公司 {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途
PL3265085T3 (pl) 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US4611078A (en) * 1983-10-26 1986-09-09 American Home Products Corporation Substituted phenylacetonitriles
US6197828B1 (en) * 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
CZ20031298A3 (cs) * 2000-10-19 2003-10-15 Teva Pharmaceutical Industries Ltd. Způsob přípravy krystalické báze venlafaxinu a nových polymorfů hydrochloridu venlafaxinu
US6906087B2 (en) 2000-10-31 2005-06-14 Ciba Specialty Chemicals Corpation Crystalline forms of venlafaxine hydrochloride
AU2001235970A1 (en) 2000-12-07 2002-06-18 Dr. Reddy's Research Foundation Novel crystalline polymorphic forms of venlafaxine hydrochloride and a process for their preparation
ATE411986T1 (de) * 2001-04-10 2008-11-15 Alembic Ltd Zwischenprodukt zur herstellung von 1-ä2- dimethylamino-1-(4-methoxyphenyl)-ethylü- cyclohexanol
AU2002348266A1 (en) * 2001-12-05 2003-06-23 Wyeth Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
WO2003050074A1 (en) * 2001-12-13 2003-06-19 Cadila Healthcare Limited Manufacture of venlafaxine hydrochloride and crystalline polymorphs thereof

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105359A1 (en) * 2000-10-31 2003-06-05 Van Der Schaaf Paul Adriaan Crystalline forms of venlafaxine hydrochloride
US6906087B2 (en) * 2000-10-31 2005-06-14 Ciba Specialty Chemicals Corpation Crystalline forms of venlafaxine hydrochloride
US20050256205A1 (en) * 2000-10-31 2005-11-17 Schaaf Paul Adriaan V D Crystalline forms of venlafaxine hydrochloride
US7045661B2 (en) 2000-10-31 2006-05-16 Ciba Specialty Chemicals Corporation Crystalline forms of venlafaxine hydrochloride
US20030109585A1 (en) * 2001-12-05 2003-06-12 Wyeth Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
US20030114536A1 (en) * 2001-12-05 2003-06-19 Wyeth Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
US20050272822A1 (en) * 2001-12-05 2005-12-08 Wyeth Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
US20060074131A1 (en) * 2001-12-05 2006-04-06 Wyeth Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
US7030164B2 (en) * 2001-12-05 2006-04-18 Wyeth Crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
WO2003082806A1 (en) * 2002-03-28 2003-10-09 Synthon B.V. Venlafaxine base

Also Published As

Publication number Publication date
HUP0700037A2 (en) 2007-05-02
CN1617848A (zh) 2005-05-18
KR20040068163A (ko) 2004-07-30
PL374273A1 (en) 2005-10-03
IS7289A (is) 2004-05-27
US6924393B2 (en) 2005-08-02
US20080167498A1 (en) 2008-07-10
EP1474379A4 (de) 2006-06-07
JP2005511668A (ja) 2005-04-28
NO20042732L (no) 2004-06-29
CA2468728A1 (en) 2003-06-12
MXPA04005193A (es) 2005-02-22
WO2003048082A3 (en) 2004-08-26
ZA200404080B (en) 2007-12-27
CN101219962A (zh) 2008-07-16
WO2003048082A2 (en) 2003-06-12
IL162171A0 (en) 2005-11-20
US20050049304A1 (en) 2005-03-03
EP1474379A2 (de) 2004-11-10
AU2002365874A1 (en) 2003-06-17
HRP20040565A2 (en) 2005-08-31
US20040220278A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
US20080167498A1 (en) Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US20020143211A1 (en) Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochlorid, processes for preparing thereof
US11739057B2 (en) Polymorphic forms of Belinostat and processes for preparation thereof
US11780810B2 (en) Intermediates for optically active piperidine derivatives and preparation methods thereof
US7728173B2 (en) Processes for preparing venlafaxine and venlafaxine hydrochloride of form I
ZA200302768B (en) Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
EP4063351A1 (de) Verfahren zur herstellung von chinolinderivatverbindungen
US20050171145A1 (en) Process for the preparation of 2-(ethoxymethyl)-tropane derivatives
EP4071139A1 (de) Kristallines lofexidin hydrochlorid
US6384244B2 (en) Process for preparing cis- aminochromanols
EP2938595B1 (de) Verfahren zur synthese eines hydrazin zur behandlung des papillomavirus
WO2009118758A2 (en) Novel crystalline forms of desvenlafaxine succinate
US20020095047A1 (en) Process for preparing hydroxychomanones and CIS-aminochromanols

Legal Events

Date Code Title Description
AS Assignment

Owner name: TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DOLITZKY, BEN-ZION;ARONHIME, JUDITH;WIZEL, SHLOMIT;AND OTHERS;REEL/FRAME:013903/0114;SIGNING DATES FROM 20020411 TO 20020430

AS Assignment

Owner name: TEVA PHARMACEUTICAL USA, INC., PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TEVA PHARMACEUTICAL INDUSTRIES, LTD.;REEL/FRAME:013916/0749

Effective date: 20030302

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION